Aberdeen Group plc Has $43.44 Million Stake in IQVIA Holdings Inc. $IQV

Aberdeen Group plc grew its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 39.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 192,696 shares of the medical research company’s stock after purchasing an additional 54,703 shares during the quarter. Aberdeen Group plc owned about 0.11% of IQVIA worth $43,436,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Eubel Brady & Suttman Asset Management Inc. bought a new stake in IQVIA in the 3rd quarter valued at $14,278,000. Eagle Rock Investment Company LLC grew its position in IQVIA by 33.6% in the 3rd quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company’s stock worth $8,800,000 after purchasing an additional 11,657 shares during the last quarter. OPTIMAS CAPITAL Ltd bought a new position in shares of IQVIA during the 3rd quarter worth about $4,008,000. Amundi raised its position in shares of IQVIA by 46.3% during the second quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock valued at $210,722,000 after buying an additional 405,250 shares during the last quarter. Finally, EDENTREE ASSET MANAGEMENT Ltd bought a new stake in shares of IQVIA in the third quarter valued at about $7,368,000. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on IQV. Morgan Stanley set a $240.00 price target on IQVIA in a research note on Wednesday, February 11th. Citigroup decreased their price objective on IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a report on Friday, February 6th. Mizuho set a $215.00 price objective on IQVIA in a research report on Monday, February 23rd. Stifel Nicolaus cut their target price on IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Finally, Jefferies Financial Group reduced their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $229.13.

IQVIA Trading Up 0.0%

Shares of IQV opened at $173.28 on Friday. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09. The stock has a market cap of $29.41 billion, a PE ratio of 22.05, a PEG ratio of 1.67 and a beta of 1.39. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04. The stock has a 50 day simple moving average of $180.07 and a 200-day simple moving average of $204.77.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating the consensus estimate of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The business had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. During the same quarter in the previous year, the firm earned $3.12 EPS. IQVIA’s quarterly revenue was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.